ADAM17 and breast cancer: We report that a high extent of ADAM17 downregulation (∆pADAM17high) during platelet activation in patients—which may occur, among others, after their interaction with metastasizing tumor cells—correlates with certain tumor stages and the occurrence of metastases in breast cancer patients.